Bristol Myers says FDA updates Camzyos label to simplify treatment
Bristol Myers (BMY) Squibb announced that the U.S. Food and Drug Administration has updated the U.S. Prescribing Information for Camzyos, simplifying treatment for patients and physicians by reducing the required echo monitoring for eligible patients in the maintenance phase and expanding patient eligibility by reducing contraindications. 'In addition to the established efficacy of Camzyos, these meaningful updates to the label reinforce the strong safety profile of the therapy. With robust clinical and real-world data and more than 15,000 patients prescribed Camzyos in the U.S., this medicine has redefined the treatment landscape for symptomatic obstructive HCM and can have a significant impact for patients living with the condition. Simplifying treatment by reducing the frequency of echo monitoring not only improves the patient experience, but will also save time for cardiologists, allowing them to treat more patients,' said Al Reba, senior vice president, Cardiovascular & Immunology Commercialization at Bristol Myers Squibb.
Discover outperforming stocks and invest smarter with Top Smart Score Stocks.
Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today's best-performing stocks on TipRanks >>
Read More on BMY:
Disclaimer & DisclosureReport an Issue
Bristol Myers price target lowered to $58 from $63 at BofA
Hold Rating on Bristol-Myers Squibb Amid Revenue Challenges and Sector-Wide Valuation Pressures
Cytokinetics price target lowered to $54 from $62 at BofA
Bristol-Myers Squibb: Hold Rating Amidst Trial Setbacks and Pipeline Challenges
Sell Rating for Bristol-Myers Squibb Due to Camzyos Trial Failure and Revenue Pressures
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
BofA Lowers PT for Old Dominion (ODFL), Maintains Neutral Rating
On June 4, BofA Securities lowered its price target for Old Dominion Freight Line, Inc. (NASDAQ:ODFL) from $183 to $172 and kept a Neutral rating on the stock. Ken Hoexter from BofA made the update following Old Dominion's mid-second quarter 2025 result. The American transport and logistics company reported a 5.8% decline year-over-year in revenue per day for May 2025, missing BofA's estimate of a 3.9% decline. Despite such, the company maintains a healthy gross profit margin of 39.75% and a trailing 12-month revenue of $5.73 billion. A large cargo ship navigating a busy port, its scale highlighting the company's marine transportation services. Hoexter also added that the company saw a 6.8% decline in shipments per day, missing the BofA's target of a 6.5% decline. The analyst also pointed out that the economic impact of the China tariffs has contributed to the weak results. Old Dominion's CEO, on the other hand, states that the company is maintaining its market share and profitability. Old Dominion Freight Line, Inc. (NASDAQ:ODFL) is a freight transportation and logistics services company that primarily offers services in the United States, Canada, and Mexico . The company also offers household moving services and expedited logistics. While we acknowledge the potential of ODFL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. Read Next: and . Disclosure. None.
Yahoo
6 hours ago
- Yahoo
BofA sees termination of Owens–Rotech deal as surprising but potentially positive
-- Bank of America said Owens & Minor's decision to terminate its planned acquisition of Rotech Healthcare was unexpected but may ultimately prove beneficial, allowing the company to refocus on its core operations and potential asset sales. The companies mutually agreed to cancel the deal after determining that regulatory clearance was unlikely. Owens & Minor (NYSE:OMI) cited antitrust concerns raised by the U.S. Federal Trade Commission in certain regional markets. The transaction was previously expected to close in the first half of 2025. OMI will incur about $100 million in costs related to the termination, including an $80 million payment to Rotech. It also plans to redeem $1 billion in notes issued in April and cancel associated loan commitments intended to fund the acquisition. 'This news is surprising to us given the competitive landscape in the durable medical equipment space,' BofA analysts wrote, noting they did not view the merger as anti-competitive. However, they said the move could benefit Owens & Minor by eliminating a complex integration and allowing management to focus on operations and cost control. Rotech had been expected to add 15 cents to earnings per share by the second year, but BofA noted the deal was highly dependent on synergies and Rotech's recent growth was weak, with revenue down 4% year-over-year in 2024. BofA reiterated its 'Underperform' rating on the stock but raised its price objective to $7.50 from $7.00, citing increased clarity on strategy and a lower debt burden. The firm expects Owens & Minor to continue pursuing smaller acquisitions in its Patient Direct business and to push ahead with a potential sale of its Products and Healthcare Services (NASDAQ:HCSG) unit. Related articles BofA sees termination of Owens–Rotech deal as surprising but potentially positive U.S. Treasury, Commerce secretaries and Trade Representative to meet Chinese reps Neo Performance Materials stock surges on buyback plan
Yahoo
6 hours ago
- Yahoo
Will Amazon's robot delivery ambitions pay off?
-- Bank of America analysts suggest that Amazon (NASDAQ:AMZN)'s burgeoning ambitions in robot delivery could yield "billions in savings," despite acknowledging significant hurdles. The e-commerce giant is reportedly exploring the use of humanoid robots for package delivery, with internal testing already underway. According to a report cited by BofA, Amazon is designing "an indoor obstacle course for humanoid robots" to train them for package delivery. They note that a report indicates the robots could eventually "ride in the back of Rivian (NASDAQ:RIVN) vans before leaping out to deliver packages." While Amazon is developing the AI software, it is expected to "test several third-party hardware solutions," with one Unitree robot estimated at around $16,000 per unit. If successful, BofA notes there could be a "large financial incentive [for Amazon] to automate." However, BofA cautions that there are still "several hurdles likely to overcome." Similar to autonomous vehicles, they expect "several years of testing before trials could begin." Obtaining regulatory approval on a local basis would also be a challenge, limiting rapid geographic expansion. Furthermore, "consumer acceptance of robot delivery would likely take time," with BofA believing it would be "much easier to automate internal processes than external." Despite these challenges, BofA maintains its Buy rating on Amazon, anticipating a substantial long-term opportunity. Their analysis estimates that "robotics in delivery could drive over $7.1bn in annual savings by 2032," not including potential savings from humanoids. BofA also sees "leading robotics infrastructure" enabling Amazon to potentially move its first-party operations to profitability as a low-cost provider and further improve third-party shipping margins, ultimately driving its long-term retail margin opportunity to 11%. Related articles Will Amazon's robot delivery ambitions pay off? Jefferies upgrades Urban Outfitters to Hold, says risk/reward now balanced Melius upgrades Deere on long-term tech moat and recurring revenue upside Sign in to access your portfolio
